

TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product

Trudy Straetemans,^{1,3,4} Anke Janssen,^{1,4} Koen Jansen,¹ Ruud Doorn,¹ Tineke Aarts,¹ Anna D.D. van Muyden,¹ Marieke Simonis,² Judith Bergboer,² Moniek de Witte,¹ Zsolt Sebestyen,¹ and Jurgen Kuball^{1,3}

¹Department of Hematology, Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; ²Cergentis, Utrecht, the Netherlands

Despite extensive usage of gene therapy medicinal products (GTMPs) in clinical studies and recent approval of chimeric antigen receptor (CAR) T cell therapy, little information has been made available on the precise molecular characterization and possible variations in terms of insert integrity and vector copy numbers of different GTMPs during the complete production chain. Within this context, we characterize $\alpha\beta$ T cells engineered to express a defined $\gamma\delta$ T cell engineered to express a defined $\gamma\delta$ T receptor (TEG) currently used in a first-in-human clinical study (NTR6541). Utilizing targeted locus amplification in combination with next generation sequencing for the vector producer clone and TEG001 products, we report on five single-nucleotide variants and nine intact vector copies integrated in the producer clone. The vector copy number in TEG001 cells was on average a factor 0.72 (SD 0.11) below that of the producer cell clone. All nucleotide variants were transferred to TEG001 without having an effect on cellular proliferation during extensive *in vitro* culture. Based on an environmental risk assessment of the five nucleotide variants present in the non-coding viral region of the TEG001 insert, there was no altered environmental impact of TEG001 cells. We conclude that TEG001 cells do not have an increased risk for malignant transformation *in vivo*.

INTRODUCTION

Adoptive cell transfer with T cells engineered to attack tumor cells, a class of so-called gene therapy medicinal products (GTMPs), involves the genetic reprogramming of T cells with defined immune receptors such as chimeric antigen receptors (CARs) or T cell receptors (TCRs). Recently, CAR T cells targeting CD19⁺ hematological malignancies have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2017 and 2018, respectively.¹ This success has accelerated the already rapid improvements of gene transfer technologies and synthetic biology that offer a wide range of possibilities to design T cells with enhanced functions. One of the major limitations of currently explored and approved CAR T cell strategies is the lack of tumor-specific targets, limiting this therapy to date to mainly B cell-related malignancies. Despite great pre-clinical efforts to find new targets, only a few candidate CAR T targets, such as B cell maturation antigen (BCMA) and the interleukin-3 (IL-3) receptor (CD123), as well as a handful of

tumor-specific $\alpha\beta$ TCRs targeting cancer-testis antigens, have reached the clinical stage of development.^{2,3} Alternative tumor-targeting strategies are needed; therefore, we introduced the concept of metabolic cancer targeting through an anti-tumor receptor derived from $\gamma\delta$ T cells and proposed to utilize $\alpha\beta$ T cells engineered to express a defined $\gamma\delta$ T cell receptor (TEGs).^{4,5} The TEG concept allows for the selection of the most potent anti-tumor $\gamma\delta$ TCR combined with the cytotoxic, proliferative, and memory formation capacities of $\alpha\beta$ T cells. Furthermore, TEG cells display identical tumor-reactivity as their parental $\gamma\delta$ T cell clone,^{5,6} suggesting that all properties from the $\gamma\delta$ TCR involved in anti-tumor reactivity are transferred to TEG cells. This concept has been recently expanded to V δ 2 negative $\gamma\delta$ TCRs expressed in $\alpha\beta$ T cells,⁷ allowing theoretically in the future potential dual reactivity of these types of immune receptor in TEG format as proposed by Melandri et al.⁸ V γ 9V δ 2 T cells sense via their non-major histocompatibility complex (MHC)-restricted TCR phosphoantigen (pAg) and small GTPase (RhoB)-dependent joint spatial and conformational changes in CD277 (CD277) at the cell surface of cancer cells^{9–11} (for review, see Sebestyen et al.¹²). TEG001 cells are engineered to express a V γ 9V δ 2 T cell-derived receptor and, as a consequence, target a broad range of tumor types independent of genetic background including primary acute myeloid leukemia (AML) and multiple myeloma (MM) cells *in vitro* and in patient-derived xenograft (PDX) models but leave healthy cells unharmed.^{4,5,13–15}

In order to further translate the TEG concept into first-in-human trials, we reported recently on the development of a Good Manufacturing Practice-compliant production protocol for the manufacturing of TEG001 cells using autologous T cells and retroviral-based gene transfer technology.^{14,16} European guidelines request

Received 19 April 2019; accepted 26 November 2019;
<https://doi.org/10.1016/j.ymthe.2019.11.030>.

³Senior author

⁴These authors contributed equally to this work.

Correspondence: Trudy Straetemans, Department of Hematology, Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

E-mail: g.c.m.straetemans@umcutrecht.nl

Correspondence: Jurgen Kuball, Department of Hematology, Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

E-mail: j.h.e.kuball@umcutrecht.nl



for GTMPs such as TEG001 the precise characterization of all different production chains in terms of integrity of insert DNA, integration site, copy numbers, and potential tumorigenesis.¹⁷ This requirement was based on the observation that different vectors, such as retrovirus, lentivirus,¹⁸ or non-viral transposons,¹⁹ generate different integration site patterns and the observation that genetic modification of hematopoietic stem cells can induce leukemia.^{20,21} In contrast, genetic modification of mature mouse and human T cells using viral vectors did so far not lead to substantial toxicities.^{22–25} For clinical studies utilizing CAR T cell products, such detailed molecular characterizations have mainly been published once side effects have been observed. For example, the disruption of the *TET2* gene by CAR transgene integration was reported to induce greater CAR T cell proliferation capacity.²⁶ Thus, we conclude that although different extensive studies have been published on individual products mainly after side effects have been observed, only little public information has been made available for many currently clinically tested or approved GTMPs (see [Table S1](#) for a comprehensive literature overview). Another observation we made regarding the currently available dataset is that insert integrity published in reports was measured only indirectly by evaluation of the expression of the introduced transgene in the final cell product, for instance, by flow cytometric analysis of CAR or TCR expression.^{27–29} Thus, to our best knowledge, there is no comprehensive information available regarding the molecular characterization of integrity of CAR or TCR transgenes on the nucleotide level throughout the complete production chain as requested by authorities, and thus from vector producer cells until final medicinal product. Finally, there are a number of reports on the manufacturing and quality-control tests of engineered T cell products that include establishment of transgene copy numbers in the final product of pre-clinical production runs,^{30–34} but only a minority of studies share vector copy numbers of infused CAR T products^{27,35–38} ([Table S1](#)). This lack of public knowledge makes it very difficult to put insert integrity and vector copy numbers of novel GTMPs within the context of existing GTMP products and clinical data linked to these products. Creating an extensive public database for GTMP production chains would allow assessing safety and potential risks of defined insertion sites, additional molecular alterations, or higher copy numbers. Therefore, we report now on the molecular integrity of the integrated DNA sequences throughout TEG001 manufacturing used for an ongoing clinical study. In addition, we propose that the applied targeted locus amplification (TLA) technology³⁹ is an elegant and rapid technology for full molecular characterization of the transgene of interest from TEG001 vector plasmid until medicinal product.

RESULTS

Mutational Variants in Non-coding Regions of the TEG001 Insert Integrated in the Master Cell Bank

Accurate transfer of the transgene DNA sequence into the genome of target cells is of utmost importance in a GTMP. Nevertheless, variations can theoretically occur in retroviral-based gene transfer technology as a consequence of the nature of the retroviral life cycle that has been continuously evolved to escape host immune

defense.^{40,41} In order to characterize potential major variations of the integrated TEG001 sequence (later referred as TEG001 insert; see [Figure S1A](#)) throughout the production process ([Figure S1B](#)), we utilized TLA technology in combination with next generation sequencing (NGS) ([Figure S2](#)). First, we set out to analyze the TEG001 insert in the virus producer cells, derived from the TEG001 master cell bank (MCB) clone 73 ([Figure S1B](#)). Two primer sets were designed targeting the TEG001 transgene to generate two independent datasets, followed by processing of the MCB cells and sequencing of PCR products. TLA technology further allowed alignment of captured sequences with the TEG001 reference plasmid sequence to determine the sequence identity of the TEG001 insert in the MCB clone. The coverage, i.e., the number of sequencing reads that align to each position, is plotted in [Figure 1A](#). Complete coverage was obtained across the TEG001 insert from position 2 to 3592 in the original plasmid reference sequence, indicating that this sequence was integrated. Although the coverage for primer set 1 between the primer positions, namely, positions 1163–1614 at the reference sequence, was low, the coverage in that region for primer set 2 was high enough (above 30-fold) to then analyze the sequence integrity.³⁹ No break-points or structural rearrangements that would have presented themselves as fusion sequences between two different parts of the insert were detected in the TEG001 insert above a 1% frequency threshold. Next, we investigated whether small sequence variants were present in the TEG001 insert above a 5% mutant allele frequency threshold and if they were found in the reads obtained by both primer sets. These small sequence variants are defined as single-nucleotide variants or small (<10-bp) insertions and deletions (InDels). There were no small sequence variants found in the protein encoding TCR γ 5-T2A- δ 5 DNA sequence; however, interestingly, four point mutations and one insertion were detected in the non-coding region of the TEG001 insert. The mutant allele frequencies (% mutation) ranged from 8% to 14%, suggesting that the single-nucleotide variants in this clonal cell population were present only in a fraction of the integrated transgene copies ([Table 1](#)).

Multiple TEG001 Insert Integration Sites within the MCB

The MCB derived from producer cell clone 73 was selected on highest virus titer production.¹⁶ Therefore, and because the five small sequence variants were detected only with a mutant allele frequency below 15%, we assumed that the TEG001 insert was integrated multiple times within this clone. In order to assess the number of TEG001 inserts integrated, TLA data originally used for the characterization of the insert integrity, as described above, were now mapped across the human genome. Because in TLA data the highest coverage is obtained on the sequences in closest proximity of the location of the primer set, coverage peaks could be used to identify the genomic position of the TEG001 transgene. TLA sequence coverage revealed nine TEG001 transgene integration sites in the MCB, seven with high coverage peaks and two with lower coverage peaks, as depicted by circles in the coverage plot ([Figure 1B](#)). In each of the nine locations, which comprise the TEG001 insert, the exact integration sites were identified based on fused DNA sequences of host genome with TEG001 transgene sequences ([Table S2](#)). All host genome-TEG001 transgene




Figure 1. Transgene Integration in Master Cell Bank Clone 73

(A) TLA sequence coverage of the TEG001 insert in MCB across the pMP71:TCR γ 5-T2A- δ 5 plasmid reference sequence. The gray vertical bars represent the number of NGS reads that align to each plasmid position and indicate the integrated TEG001 transgene sequence. The coverage generated with primer set 1 is depicted in the top panel and with primer set 2 in the bottom panels. The positions of the primers are represented by black arrows below each coverage profile. The y axis is limited to 100 \times . (B) TLA sequence coverage across the human genome using the TEG001 insert specific primer set 2. The different chromosomes are indicated on the y axis, and the chromosomal position on the x axis. Encircled are the regions containing the TEG001 transgene integration sites. Locations in smaller circles show less obvious peaks, but fusion sequences to these positions do confirm the integration sites there.

fusions were found on two identical positions in the TEG001 transgene long terminal repeat (LTR) sequence, namely, positions 558 and 3108 in the original TEG001 plasmid sequence. No transgene-transgene fusions were found. For eight out of nine integration sites, 4 bp of the human genome were duplicated and flanking the proviral DNA, in line with the biology of Moloney murine leukemia virus (MoMLV)-based retroviral integration⁴² (illustrated in Figure S3). For one out of nine integrations sites, the integration at chromosome 1 (chr1), 624 bp of the human genome sequence were duplicated instead of 4 bp; however, the fusion sites on the transgenic site were similar to the other integrations, and therefore there was no indi-

cation that the transgenic sequence was altered in this integration site. Based on these results, it was estimated that nine copies of the TEG001 transgene were accurately integrated in the MCB derived from cell clone 73.

Phenotypic Description of TEG001 Drug Product

The differentiation and homing profile of an engineered T cell product is of importance for its *in vivo* function following adoptive cell transfer.⁴³ Therefore, we extended our previous analysis¹⁶ on TEG001 cells by using a definition based on CD62L and CD45RO⁴⁴ to describe the differentiation state. The GMP-grade manufacturing

Table 1. Small Sequence Variants

		Position				
		415	568	578	606	3552
		Reference Nucleotide				
		C	T	T	A	C
		Mutation				
		G	C	C	+1C	G
Plasmid	coverage	8,655	7,316	7,327	7,273	5,208
	% mutation	0	0	0	0	0
MCB	coverage	2,051	1,750	1,785	1,802	336
	% mutation	10	9	14	10	8
TEG001-28	coverage	3,389	2,039	2,032	1,971	571
	% mutation	11	15	19	12	10
TEG001-31	coverage	2,810	17,60	1,727	1,707	480
	% mutation	13	17	20	10	11
TEG001-32	coverage	4,857	3,064	3,013	2,939	851
	% mutation	12	16	17	9	14
TEG001-33	coverage	42,660	33,494	33,461	32,897	7,017
	% mutation	12	19	17	8	11
TEG001-32_22w	coverage	20,881	16,291	17,290	16,880	3,543
	% mutation	8	23	14	5	8
TEG001-33_24w	coverage	2,516	2,299	2,360	2,316	396
	% mutation	8	3	2	3	7

Position of the five nucleotide variants and their allele frequencies in the plasmid (as control), the MCB, the TEG001 drug product samples, and the cultured TEG001 samples are shown. Position: position in the reference sequence at which the variant is found; reference nucleotide: the nucleotide present in the reference sequence at this position; mutation: the variant nucleotide identified at the indicated position, +1C indicates the insertion of 1 C after the reference A. Coverage at this position is the average between the two primer sets. % mutation, mutant allele frequency; that is, the percentage of reads that contained the variant and the average of results of the two primer sets.

protocol yielded a TEG001 product with mostly effector memory phenotype (65%–75%) but also a substantial fraction of central memory cells (10%–15%) (Figure S4).

Transgene Copy Number in TEG001 Drug Product

No clinical adverse events have been reported when using retroviral vectors to engineer mature T cells.²⁴ However, theoretically, the genotoxicity risk will increase when the number of engineered T cells infused into a patient will increase, although it is unclear whether the number of integrations sites per cell adds to this risk.⁴⁵ Although not formally assessed and stated, in discussions with the FDA five integration sites per cell are considered without increased safety risk when compared with other gene therapy products.⁴⁶ Therefore, we developed a qPCR to determine the average TEG001 vector copy number compared with the MCB producer clone 73. The transgene-specific qPCR primer/probe set was designed on the T2A region of the TEG001 transgene (primer set 1). We determined the transgene copy numbers in four TEG001 cell products, which were on average a factor 0.72 (SD 0.09) below that of the MCB clone

73 (Figure 2). The results of primer set 1 were validated with a different transgene-specific qPCR with primers and probe (primer set 2) annealing to Gag-derived sequences in the 5' LTR region of the TEG001 transgene. Detected transgene copy numbers compared with MCB clone 73 were comparable for primer sets 1 and 2 (Figure S5A). Finally, sensitivity of the qPCR was assessed by spiking TEG001_33 cells at different frequencies into a background of healthy donor PBMCs. A clear correlation (adjusted $R^2 = 0.999$, $p < 0.001$) between the frequency of TEG001_33 cells in the tested sample and the detected copy numbers was found (Figure S5B). These data suggest that we did not only develop a sensitive and reproducible method to detect persisting TEG001 in humans during the ongoing clinical study, but that the clinical study will also have a safety impact on other clinical studies by testing whether higher copy numbers for GTMPs associate with additional long-term toxicity in humans.

Mutational Variants in the Non-coding Region of the TEG001 Inserts Are Transferred to the TEG001 Drug Product

TEG001 production includes an *in vitro* expansion for 10 days after the retroviral transduction hit, before harvesting, purification, and formulation of engineered T cells into the TEG001 drug product (Figure S1B). As a consequence, also the final TEG001 drug product needs to be characterized for insert integrity, as well as frequency of mutational variants. In line with suggestions from authorities, we utilized for this analysis TEG001 drug product cells derived from four independent large-scale production runs and again performed TLA in order to first determine insert integrity. Again, the same two primer sets initially used for the analysis of the MCB were employed for the analyses, and coverage of the insert was determined by alignment with the plasmid reference sequence (Figure 3). Primer set 1 yielded 30-fold coverage or higher in all samples except for the region in between the two primers of the primer pair, positions 1163–1614. In line with insert integration in the MCB, the transgene was integrated in TEG001 drug product cells from position 2 to 3592. Again, no structural variants were detected within the insert, only the five single-nucleotide variants that were present in the MCB were transferred into TEG001 cells, and no new nucleotide variants were detected (Table 1). The mutant allele frequencies in the TEG001 samples were in the same range (from 8%–19%) as those in the MCB.

Analysis of the Small Sequence Variants

Although virus titers and protein expression of TEG001 transgene were confirmed,¹⁶ the small sequence variants found in the non-coding viral region of the TEG001 insert may have biological consequences for the medicinal product. Therefore, the five variants were further assessed in detail as indicated in Table 2. In short, all five variants occurred outside of the promoter region, and no additional start or stop codon was introduced that may lead to an alternative open reading frame or as such have influence on protein transcription. Two mutations were found in the primer binding site at positions 568 and 578 of the reference sequence. The primer binding site is essential for viral replication because it is the site where the tRNA from the host cell binds as primer to initiate the reverse transcription and replication process. In the pMP71-based TEG001 vector, the primer binding site was derived




Figure 2. TEG001 Transgene Copy Number in Drug Product

Ratios of integrated copy numbers per unit/DNA of the TEG001 transgene in four independently produced TEG001 products are compared with copy number per unit/DNA of MCB clone 73 as determined by qPCR. The mean and standard deviation of the ratio of the TEG001 products compared with the MCB clone is indicated. Values represent replicates of two qPCR experiments.

from the murine embryonic stem cell virus-5' untranslated region (MESV-5' UTR)⁴⁷ to provide a non-methylated 5' UTR to improve stability of transgene expression in murine stem cells compared with the MoMLV primer binding site.⁴⁸ The mutations found may abolish this function in murine stem cells. Effect of this specific primer binding site on protein stability in human differentiated T cells is not known. High virus titers measured by transgene expression on indicator cells imply that not only transcriptional activity was intact, but also protein stability and expression were not affected,¹⁶ even in long-term cultures of TEG001 (Figure S6). Based on these theoretical evaluations, it was concluded that the five small sequence variants did not result in an elevated safety risk of the TEG001 medicinal product for patients and the environment.

Mutational Variants Do Not Skew the TEG001 Medicinal Product in Long-Term Cultures

As indicated in the theoretical analysis of mutational variants (Table 2), we would not expect an impact of mutational variants on the growth rate of individual T cells within the TEG001 medicinal

product. In order to formally assess whether this assumption is correct and the variations in the non-coding region of the TEG001 insert would indeed not skew T cell proliferation over the original sequence, T cells from two individual TEG001 production runs (TEG001-32 and TEG001-33) were further expanded *in vitro* for up to 24 weeks with a well-established rapid expansion protocol.

TLA analysis was then repeated. In addition, compared with the reference TEG001 sequence, again the same five variants were identified in the cultured TEG001 cells (Table 1). When comparing the corresponding TEG001 drug product with the cultured samples, all frequencies decreased except only one variant in the cultured sample of TEG001-33, which increased slightly from 16% to 23%. Thus, with all limitations of an *in vitro* rapid expansion procedure, which can per definition not entirely predict outgrowth of individual clones *in vivo*, but rather reflects a forced expansion through external stimulation, sequence variants do not substantially change in frequency over time. Therefore, these five sequence variants most likely do not correlate with an elevated safety risk.

TEG001 Insert Integration in Medicinal Drug Product

The four final TEG001 drug product samples analyzed with TLA were further used to perform an integration site analysis. Genomic coverage profiles showed, as expected, a heterogeneous integration pattern on a genome-wide scale because no large coverage peaks were detected in all samples (Figure 4A). In line with this observation, many different unique integration sites, identified in the data as reads that consist in part of transgene sequence and in part of genomic sequence (genome-transgene fusion reads), supported the notion of heterogeneity (Figure 4B).

DISCUSSION

The viral vector particle, the vector backbone, and the transgene are the three components considered to be responsible for the biological effects of a GTMP;¹⁷ however, reports on a precise and complete molecular characterization of transgenes in GTMPs throughout the full production chain are scarce (Table S1). Therefore, we comprehensively characterized and report here the presence, integrity, and persistence of genetic information from plasmid vector into T cells in order to cover the whole GTMP production chain and assess early potential threats. Rapid and consistent preclinical evaluation of a complete production chain of a GTMP required also a new strategy in order to allow a sensitive but also reproducible early detection of small differences, which is applicable to any GTMP. By utilizing a combination of TLA and NGS, we report here that the protein encoding TEG001 transgene DNA sequence (TCR γ -T2A-TCR δ) consistently remained intact throughout the production process into TEG001 medicinal product. TLA technology allowed us to detect very small sequence variants in non-coding regions of the TEG001 insert in the MCB and TEG001 drug product, which appeared, however, not to lead to a growth advantage in long-term cultured TEG001 cells *in vitro*.




Figure 3. Transgene Integration in TEG001 Drug Product

Representative picture of TLA sequence coverage of the TEG001 insert in a TEG001 drug product sample (TEG001-28). Coverage is depicted across the pMP71:TCR γ -T2A- δ plasmid reference sequence; see legend to Figure 1A. Top panel: coverage generated with primer set 1; bottom panel: coverage generated with primer set 2.

In contrast with previously reported technologies for integration site analysis, such as linear-amplification-mediated PCR (LAM-PCR) techniques,^{49,50} tagmentation PCR (tag-PCR),⁵¹ a complete pipeline named INSPIRED,^{52,53} or others^{54,55} that amplify a small fragment of the transgene, TLA can most importantly combine integrity control of the complete transgene with integration site analysis. As such, this technology can be a valuable tool not only for quality control of a cellular engineered product and persistence *in vivo* but also for genotoxicity analysis in GTMP studies in case of an unexplained increase in clonal frequency of engineered cells *in vivo*. A qPCR technique has been applied in this study to relate the transgene copy number in TEG001 cells to that of the MCB clone. Interestingly, the number of integrated TEG001 inserts in the producer cell clone was estimated at nine copies per cell, and although the transgene copies per cell in TEG001 cells was calculated as being a factor 0.72 below, it still exceeded the five copy numbers per cell in TEG001. No more than five transgene copies per cell has been for many years considered as the ultimate threshold for acceptance of copy numbers for GTMPs, based on established quality-control tests used to release a lentiviral-based engineered T cell product targeting HIV-infected cells.⁴⁶ Consequently, CAR T products do not exceed this threshold.^{27,30,32,33,36} However, most recently, higher copy numbers became acceptable if defined reasoning has been provided. In contrast with CAR T cells, the introduced $\gamma\delta$ TCR needs to outcompete the endogenous TCR for CD3 molecules to be expressed at the cell surface,⁴ implying that higher copy numbers may be required for TEG001 than for CAR T products. In addition, our production process includes an enrichment step, which allows selection for engineered immune cells with only highest expression of the transgene.^{14,16} Therefore, the ongoing TEG001 trial will not only be pivotal for testing a new type of metabolic cancer targeting with engineered immune cells but also addresses important safety aspects when transgene copy numbers exceed so far considered thresholds.

Inevitably, viral gene engineering techniques imply a risk for the occurrence of mutational and structural variants in the transgene DNA sequence integrated in the host genome. Selection of a producer clone based on vector titer and transgene expression can select against a negative effect of sequence variants on packaging of the vector and protein expression and stability; however, a more in-depth molecular analysis of the transgene is required for clinical application of a GTMP. We observed that two out of the five small-nucleotide variants, located in the non-coding regions of integrated TEG001 transgene, were in the primer binding site. This retroviral region is likely to be highly sensitive for mutations because of its function as primer binding site for host tRNA.⁴⁰ In case tRNA molecules with an incomplete complementarity to the primer binding site bind and initiate reverse transcription, mutations are introduced in this region. A third variant, a single insertion, was found in the region in between the primer binding site and the packaging signal (Ψ). The other two mutations are at the junction of the R and U regions that is homolog for both the 5' and 3' LTRs, and are therefore likely the result of a single mutational event during reverse transcription. These five small-nucleotide variants did not in our perspective imply an altered or additional environmental safety risk of the TEG001 drug product over the reference viral sequences and as such were accepted by the competent authorities.

Our integration site analysis performed on TEG001 medicinal product revealed a heterogeneous integration pattern at the genome level, and heterogeneity decreased following a significant *in vitro* culture period. We conclude that none of the five small-nucleotide variants present in TEG001 cells lead to a growth advantage, indicative of the absence of an induction of an oncogenic transformation. These data support the impressive number of 1,000 patients treated with TCR and CAR-engineered T cells without the report of an oncogenic transformation of infused engineered T cells.² Nevertheless, close monitoring of any adverse events remains indispensable and is also

Table 2. Environmental Impact of Five Nucleotide Variants Identified in the TEG001 Insert

Mutation	Element	Impact
Position 415 C to G	junction of U3 to R region in 5' LTR	The mutation occurred outside the promoter region and therefore does not affect promoter activity. The mutation does not lead to the introduction of an additional start codon and will not lead to a new open reading frame (ORF). The mutation does not lead to the introduction of an additional stop codon and as such has no influence on protein transcription. It is unlikely that this mutation affects packaging, integration, and transcription, and is therefore considered neutral to the biology of the retroviral vector. In conclusion, there is no altered or additional environmental risk as a result of this mutation.
Position 568 T to C	primer binding site	Because the mutations at positions 568 and 578 are both just after the 5' LTR but in the primer binding site, their impact is considered together. The primer binding site is essential for replication because it is the site where the tRNA from the host cell binds as primer to initiate the inverse transcription and replication process. In the pMP71 vector, the primer binding site was derived from the murine embryonic stem cell virus-5' untranslated region ⁴⁷ to provide a non-methylated 5' UTR to improve stability of transgene expression in murine stem cells compared with the Moloney murine leukemia virus primer binding site. ⁴⁸ The mutations found may abolish this function in murine stem cells. The effect of this specific primer binding site on protein stability in human differentiated T cells is not known. High virus titers measured by transgene expression on indicator cells indicate that not only transcriptional activity was intact but also protein stability and expression were not affected. The mutations do not lead to the introduction of an additional start codon and as such will not lead to a new ORF. The mutations do not lead to the introduction of an additional stop codon and as such have no influence on protein transcription. It is unlikely that this mutation affects packaging, and integration resulted from their position. In conclusion, there is no altered or additional environmental risk as a result of these two mutations.
Position 578 T to C	primer binding site	The mutations do not lead to the introduction of an additional start codon and as such will not lead to a new ORF. The mutations do not lead to the introduction of an additional stop codon and as such have no influence on protein transcription. It is unlikely that this mutation affects packaging, and integration resulted from their position. In conclusion, there is no altered or additional environmental risk as a result of these two mutations.
Position 606 A +1C	after primer binding site and before packaging sequence (Ψ)	The insertion occurred outside the primer binding site and packaging sequence, and therefore it is unlikely that it affects packaging, integration, and transcription. The insertion does not lead to the introduction of an additional start codon and will not lead to a new ORF. The insertion does not lead to the introduction of an additional stop codon and as such has no influence on protein transcription. In conclusion, there is no altered or additional environmental risk as a result of this insertion.
Position 3552 C to G	junction of U3 to R region in 3' LTR	This mutation is identical to the mutation at position 415; see above. In conclusion, there is no altered or additional environmental risk as a result of this mutation.

mandatory as requested by authorities.⁴⁵ Thus, although very detailed molecular and genetic analyses were performed following clinical events post CAR T infusion,^{26,56} our suggested robust and cost-efficient genetic quality-control assay will reduce the risk for unintended side effect of GTMPs. TLA can be used to combine integration site analysis, complete transgene integrity analysis, and analysis of the neighboring DNA up to tens to hundreds of kilobases throughout the complete production chain;³⁹ however, the lead time of these sequencing-based techniques may currently be a limiting factor for implementation of these into release test programs for GTMPs.

In conclusion, we have reported an extensive molecular characterization of TEG001 transgene integrity that resulted in the approval of a phase I clinical study that did not only allow to investigate the safety and tolerability of TEG001 in patients with relapsed/refractory AML, high-risk myelodysplastic syndrome, and relapsed/refractory MM, but also will provide a valuable framework for future GTMPs.

MATERIALS AND METHODS

TEG001 manufacturing process

We reported recently on the development of a GMP-compliant TEG001 product.¹⁶ The production process included the generation

of a 293VecRD114 packaging cell clone stably integrated with the TCR γ 5-T2A- δ 5 transgene (TEG001 transgene). The TEG001 transgene is composed of codon-optimized human TCR sequences from a V γ 9V δ 2T cell clone (clone 5) obtained from a healthy donor⁵ flanked by 5' and 3' LTR sequences and is 3,634 bp in size. In the transgene cassette, the individual γ TCR and δ TCR chains have been connected with a self-cleaving T2A ribosomal skipping sequence¹⁴ (Figure S1A). Following selection of clone 73 with the highest virus titer production and generation of the MCB, the GMP-grade retroviral vector stock was produced (see Figure S1B). The TEG001 manufacturing process includes the collection of T cells via leukapheresis, followed by T cell activation and transduction with the retroviral vector. The viral vector is equipped with viral machinery to reverse transcribe its RNA into DNA encoding the $\gamma\delta$ TCR to be stably integrated into the patients' conventional $\alpha\beta$ T cells. After large-scale expansion, the cell product is harvested, concentrated, and purified to deplete untransduced cells. In-process monitoring and quality-control release tests are implemented before TEG001 is ready for infusion (Figure S1B).

Sample Collection

Plasmid DNA from the TEG001 vector was used as starting material for the production of the MCB clone 73, and a sample of this DNA




Figure 4. Heterogeneous Integration Pattern of TEG001 Insert in TEG001 Drug Product

(A) TLA sequence coverage across the human genome using the TEG001 specific primer set 1. No coverage peaks are visible. The different chromosomes are indicated on the y axis, and the chromosomal position on the x axis. One representative sample out of four is shown (TEG001-28). (B) Many integration sites are found in TEG001 drug product samples as an indication of a heterogeneous integration pattern. Coverage and number of different genome fusion sites are indicated per sample for the two positions in the LTR sequence that are fused to the human host genome. The data from primer sets 1 and 2 are combined.

was used as reference sample in TLA. The vector is named pMP71:TCR δ -T2A-TCR γ and contains: (1) the insert DNA sequence, i.e., the proviral DNA that will be inserted into the genome of the host cell; (2) the transgene DNA sequence as part of the insert, i.e., the TCR γ -T2A-TCR δ transgene cassette; and (3) the vector backbone DNA sequence not integrated into the host genome.

A total of 5×10^6 frozen cells from MCB clone 73 were used, as well as 5×10^6 TEG001 cells derived from four independent full-scale TEG001 production runs (run 28, run 31, run 32, and run 33) for TLA. Cells were taken from the TEG001 drug product and as a consequence, these cells were expanded for 10 days following retroviral transduction. TEG001 cells derived from two independent TEG001 production runs (run 32 and run 33) were expanded for 22 weeks

(TEG001-32 22w) and 24 weeks (TEG001-33 24w), respectively, according to a rapid expansion protocol.⁵⁷

Flow Cytometry

Antibodies used for flow cytometry were pan- $\gamma\delta$ TCR-phycoerythrin (PE) (clone IMMU510; Beckman Coulter), pan- $\alpha\beta$ TCR-allophycocyanin (APC) (clone IP26; eBioscience), CD8 α -PerCP-Cy5.5 (RPA-T8; BioLegend), CD4-V450 (clone RPA-T4; BD Biosciences), CD62L-FITC (fluorescein isothiocyanate) (Dreg-56; Life Technologies), and CD45RO-PE-Cy7 (UCHL-1; BD Biosciences). Samples were analyzed on BD FACSCanto II or BD LSRFortessa flow cytometer using FACSDiva software (BD Biosciences). Lymphocytes were gated based on forward scatter (FSC) and side scatter (SSC). TEGs were defined as lymphocytes being positive for $\gamma\delta$ TCR.

TLA and NGS

TLA was performed as described previously³⁹ and depicted in [Figure S2](#). Shortly, cells were crosslinked using formaldehyde, and DNA was digested with NlaIII. Next, samples were ligated, crosslinks reversed, and DNA purified. To obtain circular chimeric DNA molecules for PCR amplification, the DNA molecules were trimmed with NspI and ligated at a DNA concentration of 5 ng/μL to promote intramolecular ligation. NspI was used for its RCATGY recognition sequence that encompasses the CATG recognition sequence of NlaIII. Consequently, only a subset of NlaIII (CATG) sites was (re-) digested, generating DNA fragments of approximately 2 kb and allowing the amplification of entire restriction fragments. Following ligation, DNA was purified, and eight 25-μL PCRs, each containing 100 ng template, were pooled for sequencing. The following inverse primer sets were used in the PCRs: set 1, 5'-ATCGCCGAGACCAAGCTG-3' and 5'-CGCCATACACGCACAGGG-3'; set 2, 5'-GCCATCGTG CACACCGAG-3' and 5'-GCCGTAGATGTCCTTCTCCC-3'. The primer sets were used in individual TLA amplifications. PCR products were purified and library prepped using the Illumina NexteraXT protocol and sequenced on an Illumina Miseq sequencer.

Mapping and Sequence Alignment

Reads were mapped using BWA-SW, which is a Smith-Waterman alignment tool. This allows partial mapping, which is optimally suited for identifying break-spanning reads. The generated data were mapped against the human genome version hg19 and the TEG001 vector pMP71:TCRδ-T2A-TCRγ sequence. The resulting mapped BAM files were analyzed using IGV software.⁵⁸ For the identification of the integration sites in the MCB sample, both coverage peaks and the identified breakpoint reads were used. For the breakpoint reads in the MCB sample, the threshold was set to 1%.

qPCR

After thawing of frozen samples of the TEG001 MCB clone 73, TEG001 products and healthy donor PBMC genomic DNA (gDNA) were isolated using QIAamp DNA Blood Mini Kit (QIAGEN) according to the manufacturer's instructions. Two gene-specific primer sets for TaqMan qPCR were used: primer set 1 for the T2A linker region of the TEG001 transgene (forward primer: 5'-CTGCAACGGCGAGAAGAG-3', reverse primer: 5'-GCTGATCCGCTCCATGTTAAT-3', probe: 5'-FAM_TTTCTTCCACATC GCCGAGGTC_TAMRA-3'), and primer set 2 for the Gag sequences in the 5' LTR region of the transgene (forward primer: 5'-CTGTATCAGTTAACCTACCCGAG-3', reverse primer: 5'-GGCGTAAAACCGAAAGCAAA-3', probe: 5'-FAM_CCCAACAA AGCCACGTACCCCT_TAMRA-3'). To correct for the loss of DNA during handling of the samples in preparation for the qPCR assay, we used TaqMan Copy Number Reference Assay RNase P (Applied Biosystems). The RNase P gene has two copies per diploid cell and is used as a reference in GTMP vector copy studies.³⁴ All qPCR analyses were performed with TaqMan Universal PCR Master Mix (Applied Biosystems) on the ViiA7 Real-Time PCR system (Applied Biosystems). Each data point was evaluated in triplicates with mean values used for analysis. A seven-point standard curve

to detect copy numbers per unit/DNA was generated consisting of 10⁶ to 10¹ copies of the vector spiked into a background of 100 ng healthy donor PBMC gDNA. A five-point standard curve of 200 to 0.02 ng healthy donor PBMC gDNA for the reference assay was generated. Standard curves were included in every experiment and met predefined criteria (qPCR efficiency between 90% and 110%, adjusted R² ≥ 0.99). A total of 100 ng of gDNA of the MCB clone 73 and the TEG products was used as input in a parallel amplification reaction for both qPCR of the transgene and RNaseP reference assay. Ratios of copy number per unit/DNA of TEG001 products compared with MCB clone 73 were calculated with the method of Pfaffl, which takes the efficiencies of the qPCRs into account.⁵⁹

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.ymthe.2019.11.030>.

AUTHOR CONTRIBUTIONS

Conceptualization, T.S. and J.K.; Methodology, T.S. and J.K.; Analysis, A.J., J.B., and M.S.; Investigation, A.J., T.A., R.D., K.J., J.B., and M.S.; Writing, T.S., A.J., and J.K.; Critical Review, Z.S., J.B., M.S., and M.d.W.; Project Administration, A.D.D.v.M.; Supervision, T.S. and J.K.; Funding Acquisition, J.K. and Z.S. All named authors have made a sufficient contribution to this paper and all agreed to submit the paper in the present form.

CONFLICTS OF INTEREST

A.J., J.K., and Z.S. are inventors on different patents with γδT cell receptor sequences, recognition mechanisms, and isolation strategies. J.K. receives research funding from and is SA and shareholder of Gadeta (<https://www.gadeta.nl/>). J.B. and M.S. are employees of Gergentis. All other authors declare no competing interests.

ACKNOWLEDGMENTS

Funding for this study was provided by ZonMw grant 43400003 and VIDI-ZonMW grant 917.11.337; KWF grants UU 2010-4669, UU 2013-6426, UU 2014-6790, UU 2015-7601, and UU 2018-11393; and Gadeta to J.K.

REFERENCES

- Chabannon, C., Kuball, J., Bondanza, A., Dazzi, F., Pedrazzoli, P., Toubert, A., Ruggeri, A., Fleischhauer, K., and Bonini, C. (2018). Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. *Sci. Transl. Med.* *10*, eaap9630.
- June, C.H., and Sadelain, M. (2018). Chimeric Antigen Receptor Therapy. *N. Engl. J. Med.* *379*, 64–73.
- Ping, Y., Liu, C., and Zhang, Y. (2018). T-cell receptor-engineered T cells for cancer treatment: current status and future directions. *Protein Cell* *9*, 254–266.
- Marcu-Malina, V., Heijhuurs, S., van Buuren, M., Hartkamp, L., Strand, S., Sebestyen, Z., Scholten, K., Martens, A., and Kuball, J. (2011). Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. *Blood* *118*, 50–59.
- Gründer, C., van Dorp, S., Hol, S., Drent, E., Straetemans, T., Heijhuurs, S., Scholten, K., Scheper, W., Sebestyen, Z., Martens, A., et al. (2012). γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γδ2TCRs. *Blood* *120*, 5153–5162.
- Scheper, W., van Dorp, S., Kersting, S., Pietersma, F., Lindemans, C., Hol, S., Heijhuurs, S., Sebestyen, Z., Gründer, C., Marcu-Malina, V., et al. (2013). γδT cells

- elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. *Leukemia* 27, 1328–1338.
7. Kierkels, G.J.J., Scheper, W., Meringa, A.D., Johanna, I., Beringer, D.X., Janssen, A., Schiffler, M., Aarts-Riemens, T., Kramer, L., Straetemans, T., et al. (2019). Identification of a tumor-specific allo-HLA-restricted $\gamma\delta$ TCR. *Blood Adv.* 3, 2870–2882.
 8. Melandri, D., Zlatareva, I., Chaleil, R.A.G., Dart, R.J., Chancellor, A., Nussbaumer, O., Polyakova, O., Roberts, N.A., Wesch, D., Kabelitz, D., et al. (2018). The $\gamma\delta$ TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. *Nat. Immunol.* 19, 1352–1365.
 9. Sebestyen, Z., Scheper, W., Vyborova, A., Gu, S., Rychnavska, Z., Schiffler, M., Cleven, A., Chéneau, C., van Noorden, M., Peigné, C.M., et al. (2016). RhoB Mediates Phosphoantigen Recognition by V γ 9V δ 2 T Cell Receptor. *Cell Rep.* 15, 1973–1985.
 10. Gu, S., Sachleben, J.R., Boughter, C.T., Nawrocka, W.L., Borowska, M.T., Tarrasch, J.T., Skiniotis, G., Roux, B., and Adams, E.J. (2017). Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on V γ 9V δ 2 T cell activation. *Proc. Natl. Acad. Sci. USA* 114, E7311–E7320.
 11. Harly, C., Guillaume, Y., Nedellec, S., Peigné, C.M., Mönkkönen, H., Mönkkönen, J., Li, J., Kuball, J., Adams, E.J., Netzer, S., et al. (2012). Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human $\gamma\delta$ T-cell subset. *Blood* 120, 2269–2279.
 12. Sebestyen, Z., Prinz, I., Déchanet-Merville, J., Silva-Santos, B., and Kuball, J. (2019). Translating gammadelta ($\gamma\delta$) T cells and their receptors into cancer cell therapies. *Nat. Rev. Drug Discov.* Published online September 6, 2019. <https://doi.org/10.1038/s41573-019-0038-z>.
 13. Braham, M.V.J., Minnema, M.C., Aarts, T., Sebestyen, Z., Straetemans, T., Vyborova, A., Kuball, J., Öner, F.C., Robin, C., and Alblas, J. (2018). Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. *OncoImmunology* 7, e1434465.
 14. Straetemans, T., Gründer, C., Heijhuurs, S., Hol, S., Slaper-Cortenbach, I., Bönig, H., Sebestyen, Z., and Kuball, J. (2015). Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer. *Clin. Cancer Res.* 21, 3957–3968.
 15. Johanna, I., Straetemans, T., Heijhuurs, S., Aarts-Riemens, T., Norell, H., Bongiovanni, L., de Bruin, A., Sebestyen, Z., and Kuball, J. (2019). Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. *J. Immunother. Cancer* 7, 69.
 16. Straetemans, T., Kierkels, G.J.J., Doorn, R., Jansen, K., Heijhuurs, S., Dos Santos, J.M., van Muyden, A.D.D., Vie, H., Clemenceau, B., Raymakers, R., et al. (2018). GMP-Grade Manufacturing of T Cells Engineered to Express a Defined $\gamma\delta$ TCR. *Front. Immunol.* 9, 1062.
 17. Biasco, L., Rothe, M., Büning, H., and Schambach, A. (2017). Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy. *Mol. Ther. Methods Clin. Dev.* 8, 21–30.
 18. Serrao, E., and Engelman, A.N. (2016). Sites of retroviral DNA integration: From basic research to clinical applications. *Crit. Rev. Biochem. Mol. Biol.* 51, 26–42.
 19. Vigdal, T.J., Kaufman, C.D., Izsvák, Z., Voytas, D.F., and Ivics, Z. (2002). Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. *J. Mol. Biol.* 323, 441–452.
 20. Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010). Transfusion independence and HMG2 activation after gene therapy of human β -thalassaemia. *Nature* 467, 318–322.
 21. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. *J. Clin. Invest.* 118, 3132–3142.
 22. Recchia, A., Bonini, C., Magnani, Z., Urbinati, F., Sartori, D., Muraro, S., Tagliafico, E., Bondanza, A., Stanghellini, M.T., Bernardi, M., et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. *Proc. Natl. Acad. Sci. USA* 103, 1457–1462.
 23. Newrzela, S., Cornils, K., Li, Z., Baum, C., Brugman, M.H., Hartmann, M., Meyer, J., Hartmann, S., Hansmann, M.L., Fehse, B., and von Laer, D. (2008). Resistance of mature T cells to oncogene transformation. *Blood* 112, 2278–2286.
 24. Scholler, J., Brady, T.L., Binder-Scholl, G., Hwang, W.T., Plesa, G., Hege, K.M., Vogel, A.N., Kalos, M., Riley, J.L., Deeks, S.G., et al. (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Sci. Transl. Med.* 4, 132ra53.
 25. Biasco, L., Ambrosi, A., Pellin, D., Bartholomae, C., Brigida, I., Roncarolo, M.G., Di Serio, C., von Kalle, C., Schmidt, M., and Aiuti, A. (2011). Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. *EMBO Mol. Med.* 3, 89–101.
 26. Fraietta, J.A., Nobles, C.L., Sammons, M.A., Lundh, S., Carty, S.A., Reich, T.J., Cogdill, A.P., Morrissette, J.J.D., DeNizio, J.E., Reddy, S., et al. (2018). Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature* 558, 307–312.
 27. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., and June, C.H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci. Transl. Med.* 3, 95ra73.
 28. Chapuis, A.G., Egan, D.N., Bar, M., Schmitt, T.M., McAfee, M.S., Paulson, K.G., Voillet, V., Gottardo, R., Ragnarsson, G.B., Bleakley, M., et al. (2019). T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. *Nat. Med.* 25, 1064–1072.
 29. van Loenen, M.M., de Boer, R., van Liemp, E., Meij, P., Jedema, I., Falkenburg, J.H., and Heemskerk, M.H. (2014). A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells. *Haematologica* 99, 759–768.
 30. Lock, D., Mockel-Tenbrinck, N., Drechsel, K., Barth, C., Mauer, D., Schaser, T., Kolbe, C., Al Rawashdeh, W., Brauner, J., Hardt, O., et al. (2017). Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. *Hum. Gene Ther.* 28, 914–925.
 31. Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009). Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. *J. Immunother.* 32, 169–180.
 32. Blaeschke, F., Stenger, D., Kaeuferle, T., Willier, S., Lotfi, R., Kaiser, A.D., Assenmacher, M., Döring, M., Feucht, J., and Feuchtinger, T. (2018). Induction of a central memory and stem cell memory phenotype in functionally active CD4⁺ and CD8⁺ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19⁺ acute lymphoblastic leukemia. *Cancer Immunol. Immunother.* 67, 1053–1066.
 33. Wang, X., Naranjo, A., Brown, C.E., Bautista, C., Wong, C.W., Chang, W.C., Aguilar, B., Ostberg, J.R., Riddell, S.R., Forman, S.J., and Jensen, M.C. (2012). Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8⁺ central memory T cells manufactured at clinical scale. *J. Immunother.* 35, 689–701.
 34. Friedman, K.M., Garrett, T.E., Evans, J.W., Horton, H.M., Latimer, H.J., Seidel, S.L., Horvath, C.J., and Morgan, R.A. (2018). Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignancies by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. *Hum. Gene Ther.* 29, 585–601.
 35. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci. Transl. Med.* 6, 224ra25.
 36. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci. Transl. Med.* 5, 177ra38.
 37. Cameron, B.J., Gerry, A.B., Dukes, J., Harper, J.V., Kannan, V., Bianchi, F.C., Grand, F., Brewer, J.E., Gupta, M., Plesa, G., et al. (2013). Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. *Sci. Transl. Med.* 5, 197ra103.
 38. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., and June, C.H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N. Engl. J. Med.* 365, 725–733.
 39. de Vree, P.J., de Wit, E., Yilmaz, M., van de Heijning, M., Klous, P., Verstegen, M.J., Wan, Y., Teunissen, H., Krijger, P.H., Geeven, G., et al. (2014). Targeted sequencing

- by proximity ligation for comprehensive variant detection and local haplotyping. *Nat. Biotechnol.* 32, 1019–1025.
40. Hu, W.S., and Hughes, S.H. (2012). HIV-1 reverse transcription. *Cold Spring Harb. Perspect. Med.* 2, a006882.
 41. Parthasarathi, S., Varela-Echavarría, A., Ron, Y., Preston, B.D., and Dougherty, J.P. (1995). Genetic rearrangements occurring during a single cycle of murine leukemia virus vector replication: characterization and implications. *J. Virol.* 69, 7991–8000.
 42. Serrao, E., Ballandras-Colas, A., Cherepanov, P., Maertens, G.N., and Engelman, A.N. (2015). Key determinants of target DNA recognition by retroviral intasomes. *Retrovirology* 12, 39.
 43. Gattinoni, L., Klebanoff, C.A., Palmer, D.C., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S.E., Theoret, M.R., Rosenberg, S.A., and Restifo, N.P. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo anti-tumor efficacy of adoptively transferred CD8+ T cells. *J. Clin. Invest.* 115, 1616–1626.
 44. Restifo, N.P., and Gattinoni, L. (2013). Lineage relationship of effector and memory T cells. *Curr. Opin. Immunol.* 25, 556–563.
 45. Aiuti, A., Cossu, G., de Felipe, P., Galli, M.C., Narayanan, G., Renner, M., Stahlbom, A., Schneider, C.K., and Voltz-Girolto, C. (2013). The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis. *Hum. Gene Ther. Clin. Dev.* 24, 47–54.
 46. Dropulic, B., Schonely, K., Slepishkin, V., Lu, X., Andre, K., Boehmer, J., Bengston, K., Doub, M., Cohen, R., Berlinger, D., et al. (2003). QC Release Testing of an HIV-1 based Lentiviral Vector Lot and Transduced Cellular Product. *Bioprocess. J.* 2, 39–47.
 47. Hildinger, M., Abel, K.L., Ostertag, W., and Baum, C. (1999). Design of 5' untranslated sequences in retroviral vectors developed for medical use. *J. Virol.* 73, 4083–4089.
 48. Grez, M., Akgün, E., Hilberg, F., and Ostertag, W. (1990). Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. *Proc. Natl. Acad. Sci. USA* 87, 9202–9206.
 49. Paruzynski, A., Arens, A., Gabriel, R., Bartholomae, C.C., Scholz, S., Wang, W., Wolf, S., Glimm, H., Schmidt, M., and von Kalle, C. (2010). Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. *Nat. Protoc.* 5, 1379–1395.
 50. Schmidt, M., Schwarzwaelder, K., Bartholomae, C., Zaoui, K., Ball, C., Pilz, I., Braun, S., Glimm, H., and von Kalle, C. (2007). High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). *Nat. Methods* 4, 1051–1057.
 51. Hamada, M., Nishio, N., Okuno, Y., Suzuki, S., Kawashima, N., Muramatsu, H., Tsubota, S., Wilson, M.H., Morita, D., Kataoka, S., et al. (2018). Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR. *EBioMedicine* 34, 18–26.
 52. Sherman, E., Nobles, C., Berry, C.C., Six, E., Wu, Y., Dryga, A., Malani, N., Male, F., Reddy, S., Bailey, A., et al. (2016). INSPIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes. *Mol. Ther. Methods Clin. Dev.* 4, 39–49.
 53. Berry, C.C., Nobles, C., Six, E., Wu, Y., Malani, N., Sherman, E., Dryga, A., Everett, J.K., Male, F., Bailey, A., et al. (2016). INSPIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions. *Mol. Ther. Methods Clin. Dev.* 4, 17–26.
 54. Wang, G.P., Berry, C.C., Malani, N., Leboulch, P., Fischer, A., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., and Bushman, F.D. (2010). Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. *Blood* 115, 4356–4366.
 55. Brady, T., Roth, S.L., Malani, N., Wang, G.P., Berry, C.C., Leboulch, P., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., Papapetrou, E.P., Sadelain, M., et al. (2011). A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. *Nucleic Acids Res.* 39, e72.
 56. Ruella, M., Xu, J., Barrett, D.M., Fraietta, J.A., Reich, T.J., Ambrose, D.E., Klichinsky, M., Shestova, O., Patel, P.R., Kulikovskaya, I., et al. (2018). Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nat. Med.* 24, 1499–1503.
 57. Voss, R.H., Kuball, J., and Theobald, M. (2005). Designing TCR for cancer immunotherapy. *Methods Mol. Med.* 109, 229–256.
 58. Robinson, J.T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., and Mesirov, J.P. (2011). Integrative genomics viewer. *Nat. Biotechnol.* 29, 24–26.
 59. Pfaffl. (2001). A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Research.* <https://doi.org/10.1093/nar/29.9.e45>.

YMTHE, Volume 28

Supplemental Information

TEG001 Insert Integrity from Vector


Producer Cells until Medicinal Product

Trudy Straetemans, Anke Janssen, Koen Jansen, Ruud Doorn, Tineke Aarts, Anna D.D. van Muyden, Marieke Simonis, Judith Bergboer, Moniek de Witte, Zsolt Sebestyen, and Jurgen Kuball

Supplemental Information

Figure S1. TEG001 transgene in the manufacturing process

A



B




Figure S1. TEG001 transgene in the manufacturing process

A. Schematic picture of the TEG001 transgene DNA. LTR = Long Terminal Repeat; SD = Splice Donor site; SA = Splice Acceptor; Ψ = Packaging signal; PBS = endogenous primer binding site for initiation of retroviral inverse transcription

MPSV= Myeloproliferative Sarcoma Virus; SFFV= Spleen Focus Forming Virus; MESV= Murine Embryonic Stem cell Virus; T2A = 2A ribosomal skipping sequence derived from *Thosea Asigna* Virus. **B.** TEG001 transgene in the manufacturing chain.

1. TEG001 transgene from pMP71-based retroviral vector is stably integrated into the 293VecRD114 packaging cell genome followed by selection of a single cell clone to expand and produce the master cell bank (MCB).

2. From the MCB a GMP-lot vector supernatant was produced and released at a dedicated manufacturing site. Viral particles contain TEG001 proviral DNA.

3. Patient derived T cells are activated and transduced with viral particles to insert the TEG001 transgene and express the tumor-specific $\gamma\delta$ TCR, followed by expansion and purification.

4. TEG001 drug product is formulated and released to be infused into the patient.

Figure S2. Targeted Locus Amplification





Figure S2. Schematic representation of TLA technology

First step in the TLA protocol is cross-linking of the DNA in the cells. Next the cross-linked DNA is digested, ligated and isolated. Overall, these steps lead to reshuffling of the DNA in the input material, which are millions of cells. In this reshuffling step the original physical proximity of DNA sequences is a key factor in this random process. Therefore, a large region can be targeted and sequenced specifically. The specific region of interest, in this case the transgene sequence, is amplified by PCR using transgene specific primer sets. Finally, NGS sequencing provides the data sets of interest.

Figure S3. TEG001 integration

A. Schematic representation of the plasmid reference



B. Schematic representation of the integration in the genome




Figure S3. Illustration of TEG001 insert integration

A. Schematic representation of the plasmid reference sequence indicating the positions that fuse to the genome. As a result of retroviral integration and replication process from viral RNA into the genome, the fusion sites are not at the 5' and 3' outer ends of the sequence. **B.** All genome fusions are found with the same two positions within the TEG001 transgene, namely positions 558 and 3108 and how these fusion sites in the transgenic sequence correspond to a genomic integration is shown. 4 bp of the human host genome were duplicated at the site of integration.

Figure S4. TEG001 medicinal product contains central memory and effector memory T cells




Figure S4. Differentiation phenotype of TEG001 medicinal product

TEG001 cells have a predominant effector-memory phenotype. The phenotype of TEG001 medicinal product derived from five different healthy donors was determined by measuring CD45RO in combination with CD62L expression. CD45RO⁻/CD62L⁺ is considered as naive, CD45RO⁺/CD62L⁺ as central memory (cm), CD45RO⁺/CD62L⁻ as effector memory (em), and CD45RO⁻/CD62L⁻ as effector (eff).

Figure S5. TEG001 qPCR quality controls




Figure S5. Quality controls for gene specific qPCR to detect copy numbers TEG001 transgene

A. Copy numbers per unit/DNA are compared to copy number per unit/DNA of MCB clone #73 for two different primer sets for qPCR are shown for TEG001_28 and TEG001_33 cell product.

Experiment was performed in triplicates, mean copy number per primer set is shown. **B.** TEG001_33 cells were spiked in different concentrations (0.2%, 2%, 20% and 100%) into a background of healthy donor PBMC's. Relation between the percentage of spiked TEG001 cells and the copy number of TEG001 insert per ng DNA is shown. Experiment was performed in duplicates, mean copy number per frequency is shown.

Figure S6




Figure S6. Stable expression of $\gamma\delta$ TCR protein in cultured TEG001 cells

T cells from healthy donor apheresis material was used to produce TEG001 cells according to ¹⁶. Long-term $\gamma\delta$ TCR expression was measured by flow cytometry after 24 weeks of *in vitro* culture using a rapid expansion protocol, including a bi-weekly stimulation with feeder cells and cytokines.

Table S1 Comprehensive overview of molecular characterization of CAR T and TCR engineered T cell products

retro = gamma retroviral vector, lenti = lentiviral vector, transient = transient lentiviral transfection of GMP packaging cell line, nr = not reported, na = not applicable, X = Reported, RC = Release Criterion for medicinal product

Product	Clinical trial identifier	Vector carrier	Master cell bank				Medicinal Infusion Product			Reference
			Transgene Integrity	Vector Copy Numbers	Insertion Site	Reference to GMP production	Transgene Integrity	Vector Copy Numbers	Insertion Site	
CAR T cell clinical trial reports										
CD19-28z	NCT00924326 NCT01087294	retro	nr	nr	nr	1	nr	nr	nr	2-5
CD19-28z	NCT01593696	retro	nr	nr	nr	1, 6	nr	nr	nr	7
CD19-28z	NCT02348216	retro	nr	nr	nr	-	nr	nr	nr	8, 9
CD19-28z	NCT00466531	retro	Reported - data not shown	Reported - data not shown	nr	10	nr	nr	nr	11
CD19-28z	NCT01044069	retro	Reported - data not shown	Reported - data not shown	nr	10	nr	X individual VCN/cell	nr	12, 13
CD4z	NCT0101341, ¹⁴ and ¹⁵	retro	nr	nr	nr	14	nr	X individual VCN/cell	X	14, 16
CTL019 CD19-41BBz	NCT01029366	lenti	na	na	na		nr	X individual VCN/cell	nr	17, 18
CTL019 CD19-41BBz	NCT01029366	lenti	na	na	na		nr	X Mean VCN/cell of released products	nr	19
CTL019 CD19-41BBz	NCT01626495	lenti	na	na	na		nr	nr	nr	20
CTL019 CD19-41BBz	NCT01626495 NCT01029366	lenti	na	na	na		nr	RC: 0.02-4 VCN/cell, not per individual product	nr	21
CTL019 CD19-41BBz	NCT01029366	lenti	na	na	na		X	nr	X	22
CTL019 CD19-41BBz	NCT01626495	lenti	na	na	na		X in leukemic cells	nr	X	23
CTL019 CD19-41BBz	NCT02435849	lenti	na	na	na		nr	nr	nr	24
CART-meso-41BBz	NCT02159716	lenti	na	na	na		nr	nr	nr	25
CD19-CD28TM-41BBz	NCT01865617	lenti	na	na	na		nr	nr	nr	26, 27
CD20-CD28TM-41BBz	NCT00621452	electoporation	na	na	na		nr	nr	nr	28

GD2 CAR	NCT00085930	retro	Reported - data not shown	nr	nr	29	nr	nr	nr	29, 30
BCMA 41BBz	NCT02658929	lenti	na	na	na		nr	nr	nr	31
TCR T cell clinical trial reports										
NY-ESO ^{c259} TCR	NCT01352286	lenti	na	na	na		nr	nr	nr	32, 33
NY-ESO TCR	NCT00670748	retro	nr	nr	nr	34	nr	nr	nr	35
Mart-1 TCR gp100 TCR	NCI-07-C-0174 NCI-07-C-0175	retro	nr	nr	nr		nr	nr	nr	34, 36, 37
MAGE-A3 TCR	NCT0135040 NCT01352286	lenti	na	na	na		nr	X VCN/cell of individual products	nr	38, 39
WT-1 TCR	NCT01640301	lenti	na	na	na		nr	RC: < 5 VCN/cell Not per individual product reported	nr	40
Pre-clinical reports										
CD20 CAR	-	lenti	na	na	na		nr	X	nr	41
CD19-41BBz CAR	-	lenti	na	na	na		nr	X mean and maximum VCN/cell, not per individual product	nr	42
CD19 CAR	IND #14645	lenti	na	na	na		nr	X VCN/cell per individual products	nr	43
BCMA CAR	NCT02658929	lenti	na	na	na		nr	X	nr	44
Mart-1 1D3 TCR	NTR3539	retro	Reported - data not shown	nr	nr		nr	nr	nr	45
mF5Mart-1 TCR F5Mart-1 TCR CD19 CAR CEA CAR 2G1 TCR	-	retro	nr	nr	nr	46	nr	nr	nr	46, 47
This report										
TEG001	NTR6541	retro	X	X	X	This report	X	X	X	This report

Table S1 references

1. Kochenderfer, J.N., et al., *Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor*. Journal of Immunotherapy, 2009. **32**(7): p. 689-702.
2. Kochenderfer, J.N., et al., *Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation*. Blood, 2013. **122**(25): p. 4129-4139.
3. Kochenderfer, J.N., et al., *B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells*. Blood, 2012. **119**(12): p. 2709-2720.
4. Kochenderfer, J.N., et al., *Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19*. Blood, 2010. **116**(20): p. 4099-4102.
5. Kochenderfer, J.N., et al., *Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels*. Journal of Clinical Oncology, 2017. **35**(16).
6. Tumaini, B., et al., *Simplified process for the production of anti-CD19-CAR-engineered T cells*. Cytotherapy, 2013. **15**(11): p. 1406-1415.
7. Lee, D.W., et al., *T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial*. Lancet, 2015. **385**(9967): p. 517-528.
8. Neelapu, S.S., et al., *Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma*. New England Journal of Medicine, 2017. **377**(26): p. 2531-2544.
9. Locke, F.L., et al., *Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma*. Molecular Therapy, 2017. **25**(1): p. 285-295.
10. Hollyman, D., et al., *Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy*. J Immunother, 2009. **32**(2): p. 169-80.
11. Brentjens, R.J., et al., *Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias*. Blood, 2011. **118**(18): p. 4817-4828.
12. Brentjens, R.J., et al., *CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia*. Science Translational Medicine, 2013. **5**(177).
13. Davila, M.L., et al., *Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia*. Sci Transl Med, 2014. **6**(224): p. 224ra25.
14. Mitsuyasu, R.T., et al., *Prolonged survival and tissue trafficking following adoptive transfer of CD4 zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects*. Blood, 2000. **96**(3): p. 785-793.
15. Deeks, S.G., et al., *A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy*. Molecular Therapy, 2002. **5**(6): p. 788-797.
16. Scholler, J., et al., *Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells*. Sci Transl Med, 2012. **4**(132): p. 132ra53.
17. Kalos, M., et al., *T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia*. Sci Transl Med, 2011. **3**(95): p. 95ra73.
18. Porter, D.L., et al., *Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia*. New England Journal of Medicine, 2011. **365**(8): p. 725-733.
19. Porter, D.L., et al., *Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia*. Science Translational Medicine, 2015. **7**(303).
20. Grupp, S.A., et al., *Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia*. New England Journal of Medicine, 2013. **368**(16): p. 1509-1518.
21. Maude, S.L., et al., *Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia*. New England Journal of Medicine, 2014. **371**(16): p. 1507-1517.
22. Fraietta, J.A., et al., *Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells*. Nature, 2018. **558**(7709): p. 307-312.
23. Ruella, M., et al., *Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell*. Nat Med, 2018. **24**(10): p. 1499-1503.
24. Maude, S.L., et al., *Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia*. New England Journal of Medicine, 2018. **378**(5): p. 439-448.
25. Haas, A.R., et al., *Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers*. Mol Ther, 2019.
26. Turtle, C.J., et al., *CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients*. Journal of Clinical Investigation, 2016. **126**(6): p. 2123-2138.
27. Turtle, C.J., et al., *Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8(+) and CD4(+) CD19-specific chimeric antigen receptor-modified T cells*. Science Translational Medicine, 2016. **8**(355).
28. Till, B.G., et al., *CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results*. Blood, 2012. **119**(17): p. 3940-3950.
29. Pule, M.A., et al., *Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma*. Nature Medicine, 2008. **14**(11): p. 1264-1270.
30. Louis, C.U., et al., *Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma*. Blood, 2011. **118**(23): p. 6050-6056.
31. Raje, N., et al., *Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma*. New England Journal of Medicine, 2019. **380**(18): p. 1726-1737.
32. Rapoport, A.P., et al., *NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma*. Nature Medicine, 2015. **21**(8): p. 914-921.
33. Stadtmayer, E.A., et al., *Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma*. Blood Advances, 2019. **3**(13): p. 2022-2034.
34. Johnson, L.A., et al., *Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen*. Blood, 2009. **114**(3): p. 535-546.
35. Robbins, P.F., et al., *A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response*. Clinical Cancer Research, 2015. **21**(5): p. 1019-1027.

36. Chodon, T., et al., *Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma*. *Clinical Cancer Research*, 2014. **20**(9): p. 2457-2465.
37. Morgan, R.A., et al., *Cancer regression in patients after transfer of genetically engineered lymphocytes*. *Science*, 2006. **314**(5796): p. 126-129.
38. Cameron, B.J., et al., *Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells*. *Science Translational Medicine*, 2013. **5**(197).
39. Linette, G.P., et al., *Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma*. *Blood*, 2013. **122**(6): p. 863-871.
40. Chapuis, A.G., et al., *T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant*. *Nat Med*, 2019. **25**(7): p. 1064-1072.
41. Lock, D., et al., *Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use*. *Hum Gene Ther*, 2017. **28**(10): p. 914-925.
42. Blaeschke, F., et al., *Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia*. *Cancer Immunol Immunother*, 2018. **67**(7): p. 1053-1066.
43. Wang, X., et al., *Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale*. *J Immunother*, 2012. **35**(9): p. 689-701.
44. Friedman, K.M., et al., *Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignancies by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells*. *Hum Gene Ther*, 2018. **29**(5): p. 585-601.
45. Gomez-Eerland, R., et al., *Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype*. *Hum Gene Ther Methods*, 2014. **25**(5): p. 277-87.
46. Feldman, S.A., et al., *Rapid Production of Clinical-Grade Gammaretroviral Vectors in Expanded Surface Roller Bottles Using a "Modified" Step-Filtration Process for Clearance of Packaging Cells*. *Human Gene Therapy*, 2011. **22**(1): p. 107-115.
47. Lu, T.Y.L., et al., *A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies*. *Human Gene Therapy Methods*, 2016. **27**(6): p. 209-218.

Table S2. Overview of the exact locations of the 9 integrations of the TEG001 transgene in genome of the MCB.

sequence 1	position 1	orientation 1	sequence 2	position 2	orientation 2
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr1	28970905	head
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr1	28971527	tail
pMP71_TCR γ 5-T2A- δ 5	559	tail	chr1	234508872	tail
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr1	234508871	head
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr11	66667547	tail
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr11	66667544	head
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr2	69533753	head
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr2	69533748	tail
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr22	17857891	tail
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr22	17857887	head
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr5	99110063	head
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr5	99110066	tail
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr6	108183211	head
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr6	108183215	tail
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr6	132721404	tail
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr6	132721407	head
pMP71_TCR γ 5-T2A- δ 5	558	tail	chr9	83990726	head
pMP71_TCR γ 5-T2A- δ 5	3108	head	chr9	83990729	tail